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Aim. The object of this study was to implement computer-aided design of the water-soluble analog of glycolipid
b-galactosylceramide (b-GalCer), which presents a potential HIV-1 entry inhibitor, by the analysis of intermole-
cular interactions of  b-GalCer with the central region of the virus envelope gp120 V3 loop followed by synthesis
of this glycolipid derivative and testing for antiviral activity. Methods. To reach the object of view, computer mo- 
deling procedures, such as quantum chemical calculations, molecular docking, molecular dynamics and free
energy simulations, were involved in the studies in conjunction with chemical synthesis and anti-HIV-1 assay me-
thods. Results. As a result, the high probability of exhibiting of antiviral activity was predicted for the designed
b-GalCer analog. The data of molecular modeling were confirmed by those of primary medical trials of the syn-
thesized compound. Conclusions. In the light of the findings obtained, the designed analog of  b-GalCer may be
considered as the basic structure for simulation of its more potent structural forms and for posterior selection of
drug candidates most promising for synthesis and anti-HIV-1 assays.
Keywords: HIV-1 gp120 V3 loop, glycolipids, computer modeling, chemical synthesis, anti-AIDS drugs.
Introduction. The HIV-1 V3 loop plays a central role in
the biology of the HIV-1 envelope glycoprotein gp120
as a principal target for neutralizing antibodies, and as a 
major determinant in the switch from the non-syncy-
tium-inducing to the syncytium-inducing form of HIV-1
that is associated with accelerated disease progression.
The HIV-1 cell entry is mediated by the sequential inter-
actions of gp120 with the receptor CD4 and a co-recep-
tor, usually CCR5 or CXCR4, depending on the indivi-
dual virion, and the HIV-1 V3 loop is crucially invol-
ved in this process (reviewed in [1, 2]). Although the
V3 loop is a promising target for anti-HIV-1 drug de-
sign, its high sequence variability is a major complica-
ting factor [3]. However, the latest findings obtained by 
comparison of the 3D V3 structures in various HIV-1
isolates and different environments make it clear that the 
HIV-1 V3 loop forms a series of conserved structural
motifs, which include residues crucial for cell tropism
[2, 4–6]. It is assumed that these V3 sites represent poten-
tial HIV-1 vulnerable spots and, therefore, provide a blue-
print for the design of novel small-molecule inhibitors
that target the invariant elements of the HIV-1 V3 loop. 
In the light of these observations, the strategy for anti-
HIV-1 drug discovery aimed at the identification of co-
receptor antagonists that are able to efficiently mask
these segments of the V3 loop, which are conserved in
diverse viral strains, is highly challenging [2].
There are a number of promising ligands for V3 that, 
according to empirical observations, exhibit a high
affinity to the HIV-1 gp120 V3 loop and, for this rea-
ISSN 0233–7657. Biopolymers and Cell. 2012. Vol. 28. N 6. P. 468–476 doi 10.7124/bc.000139 
Ó  Institute of Molecular Biology and Genetics, NAS of Ukraine, 2012 
469
COMPUTER-AIDED DESIGN OF NOVEL HIV-1 ENTRY INHIBITORS BLOCKING THE VIRUS ENVELOPE gp120 V3 LOOP
son, may be implicated in the V3-based anti-AIDS drug 
studies (reviewed in [2]). In particular, b-galactosyl-
ceramide (b-GalCer) forms on the surface of some sus-
ceptible host cells the primary receptor for HIV-1 alter- 
native to CD4, which is used by the virus to enter macro-
phages and T-lymphocytes (e. g., [7]). Furthermore,
some water soluble analogs of this glycosphingolipid
have been shown to inhibit cell tropism by specific bin- 
ding to V3 (e. g., [8]). In studies [8–10], the region re-
cognized by a synthetic water soluble analog of b-Gal
Cer was mapped to the envelope gp120 amino acids
318–323, which correspond to the core V3 sequence
Gly-Pro-Gly-Arg-Ala-Phe that has been previously
identified to be the structurally invariant V3 site [2, 4,
6]. The findings of a study [8] have shown that synthe-
tic analogs of b-GalCer can inhibit the HIV-1 entry
both into CD4– and CD4+ cells by masking the HIV-1
V3 loop. Specific interactions of the HIV-1 V3 loop
with b-GalCer were also specified in a study of Ham-
mache and coauthors [11] by measuring surface tension 
variations occurring on gp120 binding to monolayers
of glycolipids. In a recent study [12], glycoside analogs 
of b-GalCer have also been shown to block the enve-
lope gp120 V3 loop. 
Scanning the Protein Data Bank [13] shows that cur-
rently it contains the information on the V3 loops from
some HIV-1 isolates as well as on a number of glycoli-
pids including GalCer; however, there is no evidence
for their complexes in this structural database (view at
http://www.rcsb.org/pdb/). In the lack of empirical da-
ta, the use of computer modeling is one of the most ra-
tional modes to obtain this information, which is requi-
red for the structure-based design of novel potent anti-
HIV-1 drugs on the framework of b-GalCer. In this con-
nection, an integrated computational approach invol-
ving theoretical procedures, such as quantum chemist-
ry computations (e. g., [14]), molecular dynamics (e. g., 
[15]), molecular docking (e. g., [16]), free energy cal-
culations (e. g., [17]), etc. should be of great assistance
in this effort [2]. At the same time, the usage of mole-
cular docking for imitating the process of forming the
V3 loop/glycolipid complexes followed by molecular
dynamics and free energy calculations may provide a
rationale for the development of small molecules to
block this functionally important site of the envelope
gp120 protein.
The goals of this study were to build by bioinfor-
matics tools the structural complexes of b-GalCer with
the V3 loop peptides Gly-Pro-Gly-Arg/Gln-Ala-Phe
imitating the most probable binding site for glycolipids 
[8–10] and, based on their energy and geometric para-
meters, to carry out the computer-aided design of b-Gal
Cer water-soluble analog (b-GalCer-WSA), which is
capable of specific and effective interactions with V3,
followed by its synthesis and anti-HIV-1 assay.
To reach the objectives, the following problems
were solved: (i) the 3D structure of b-GalCer was gene-
rated and its dynamic characteristics were examined;
(ii) the structural complexes of b-GalCer with the V3 lo- 
op peptides were built and b-GalCer-WSA, a potential
HIV-1 entry inhibitor, was constructed from the analy-
sis of intermolecular interactions, which appear in the-
se supramolecular ensembles; (iii) the 3D structures
and dynamic features of this b-GalCer-WSA were ana-
lyzed; (iv) dynamic models for the complexes of glyco- 
lipid with the V3 loop peptides were computed and
their conformational stability was estimated by free
energy calculations; (v) b-GalCer-WSA designed by
computer modeling was synthesized and tested for an-
tiviral activity. 
With the calculated data, the binding of b-GalCer to 
the V3 peptides should result in forming the stable struc- 
tural complexes, and a synthetic copy of the simulated
b-GalCer-WSA should preserve a strong attraction to
the HIV-1 V3 loop characteristic of the native molecu-
le. These in silico data were validated by the anti-HIV-
1 assay of the synthesized compound.
Materials and methods. Modeling 3D structures
of b-GalCer and its analog. The X-ray conformation of 
a-GalCer, which appears in the complex of CD1d gly-
coprotein with b-2-microglobulin (PDB ID 1ZT4;
http://rcsb.org/pdb/) [13], was used for computing the
3D structures of b-GalCer and its modified form. To
design the starting model of b-GalCer, the a-GalCer
structure was subject to the following modifications by
the ChemDraw computer graphics tools (http://www.
cambridgesoft.com/software/): (i) a-D-galactopyrano- 
se was substituted by b-D-galactopyranose; (ii) 4-hyd-
roxydihydrosphingosine was transformed into sphingo-
sine by deletion of C4-hydroxyl group and substitution
for an ordinary C4-C5 bond by a double bond in trans
conformation; (iii) cerotic acid CH3(CH2)24COOH was
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converted into eicosanoic acid CH3(CH2)18COOH. The
structure of b-GalCer obtained in this way was utilized
to generate the starting model of water soluble analog
of the glycolipid, which was designed by the deletion
of its fatty acid residue.
Modeling the 3D structures of glycolipids was per-
formed by quantum-chemical simulations using the
GAMESS program package [14, 18]. To calculate the
molecular electronic configuration, the self-consistent
field method of Hartree-Fock with 6-31G* basis set
was engaged in the studies [19]. Geometric parameters
of the molecules were optimized by the modified New-
ton-Raphson method [20]. To compute characteristic
atomic charges, the Restricted Electrostatic Potential
fitting procedure was used [21, 22]. 
Examining dynamic properties of glycolipids. Mo-
lecular dynamics (MD) simulations were involved in
the studies by the Amber 10 software tools [23]. The
scheme using explicit definition of the solution proper-
ties was applied. Before the MD computations, the star- 
ting structures of glycolipids were minimized by the
conjugate gradient method and placed in truncated octa-
hedral cells, allowing one to impose periodic boundary
conditions on the system under consideration. Then the 
free space of these cells was filled by water molecules
followed by heating the system from 0 to 300 K during
100 ps time domain at fixed volume. In the next point,
the pressure was equilibrated within 100 ps by dynamic 
changes of the cell linear dimensions according to the
scheme of Berendsen and coauthors [24]. In the steps of 
heating and pressure balancing, additional constraints
on the positions of glycolipids atoms were imposed by
the cusp form potential using the force constant equal
to 2.0 kcal/mol. Subsequently, these restrictions were
raised and the MD simulations were carried out in the
Gibbs thermodynamic conditions within 20.5 ns time
domain. At the same time, the first 0.5 ns were suppo-
sed to be the relaxation time for the structures of inte-
rest. In the final stage, clustering of the structures ap-
pearing in the MD trajectories of glycolipids was im-
plemented. 
Analysis of the MD trajectories of glycolipids ma-
de it clear that they form a limited number of structures, 
which, in both cases, may be divided into three clusters
adequately describing their conformational mobility
(Fig. 1). 
Building dynamic structural models of the V3 loop
peptides. In the calculations, the HIV-1 V3 loop was
represented by its central region Gly-Pro-Gly-Gln/
Arg-Ala-Phe that greatly contributes to specific inter-
actions of gp120 with glycolipids [8–10]. Conforma-
tions of the V3 peptides, which appear in the 3D struc-
tures of the V3 loops from the HIV-1 subtypes A (pepti-
de Gly-Pro-Gly-Gln-Ala-Phe) [4] and B (Gly-Pro-Gly- 
Arg-Ala-Phe) [5], were used as the starting points. The
MD computations were carried out by the AMBER 10
package [23]. In the closing step, clustering of the cal-
culated structures was executed. 
As follows from the calculated data, the conforma-
tional mobility of the V3 peptides may be characterized 
by four clusters, the averaged structures of which (Fig.
2) were used in molecular docking simulations.
Generating structural complexes of glycolipids with
the V3 peptides. To simulate the structural complexes,
the UCSF DOCK 6.3 program package [25] was em-
ployed in the variant of rigid-body molecular docking.
All possible molecular structures found by the MD cal-
culations (Fig. 1 and 2) were involved in the studies to
indirectly take into account their conformational flexi-
bility. As a result of docking simulations, eight most
probable complexes were selected for each V3/glyco-
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Claster 1 Claster 2 Claster 3A
B
39 % 39 % 22 %
36 % 32 % 32 %
1,98 C 1,75 C 1,81 C
2.40 C 2.28 C 2.85 C
Fig. 1. 3D structures of b-GalCer (A) and its water soluble analog (B)
obtained by subdividing the glycolipid MD trajectories into three
structural clusters. The averaged structures are shown for each cluster.
The populations of clusters and average distances to their centers are
given below
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lipid pair according to the values of the DOCK 6.3 ob-
jective function [25]. Subsequently, dynamic characte-
ristics of these complexes were examined within 2.5 ns
time domain by the MD simulations in implicit sol-
vent. At that, the first 1.5 ns were assumed to be the time, 
which is necessary for the structure to reach the equilib-
rium. For every structural complex, the 1.0 ns segments 
of the MD trajectories belonging to its best-energy re-
presentatives were merged and the final trajectory ob-
tained in this way was involved in the binding free ener-
gy calculations by the MM-PB/SA method [17]. These
computations were carried out by the AMBER 10 pack-
age [23]. 
All simulations were run on SKIF K-1000 compu-
ter cluster [26]. 
Synthesis of b-GalCer-WSA. b-GalCer-WSA (psy-
chosine) was synthesized by deacylation of pig brain ce-
rebrosides extracted by the method [27] with some mo-
difications. Cerebrosides (1 g) were suspended in 18 ml 
of butanol-1 in a round-bottom flask. Then the solution
of 1.6 g potassium hydroxide in 2 ml of water was ad-
ded and the mixture was refluxed for 2 hours. The mix-
ture was cooled and 20 ml of isopropanol, 20 ml of me-
thanol, 10 ml of chloroform and 4 ml of 20 % sulfuric
acid were added. The mixture obtained was filtered and 
the supernatant was evaporated with toluene (5 ml) to
15 ml volume. 
After addition of methanol (25 ml), hexane (25 ml)
and water (20 ml), the mixture was shaken in the separa-
ting funnel and the bottom water layer was separated
and washed twice with hexane (25 ml). Subsequently,
20 ml of water and 20 ml of chloroform were added; the 
bottom layer was separated and rotary evaporated. As a 
result, viscous yellowish fluid was obtained. To extract
pure psyhcosine, 20 ml of chloroform and 20 ml of me-
thanol were added and the solution was run through alu-
mina and washed with 100 ml of methanol. The overall
yield was 300 mg (50 %).
Testing of  b-GalCer-WSA for anti-HIV-1 activity
in vitro. The T-lymphoblast cell line MT-4 obtained by 
co-cultivation of human T-cells with infected HTLV-
1 lymphocytes was used. The sowing doze was (4–
5)×105 cells/ml on the RPMI-1640 growth medium
(«Sigma», Germany), which included 10 % fetal calf
serum, 2.0 mM of L-glutamine, 10 mM of HEPES,
50.0 µg/ml of gentamicin sulfate and 10.0 µg/ml of ty-
losine tartrate) at 37 °C in the atmosphere of 5 % carbon
dioxide (CO2). The passages were repeated in every 72 h 
to determine the cell vitality by 0.2 % trypan blue
staining.
The HIV-1zmb rapid/high strain isolated from the vi-
rus-positive person living in Belarus was involved in
the tests. The averaged virus titer was 6.0 log TCID50.
The sample stock dilution (10.0 mg/ml) was made on
distillated water and kept during four days at 4 °C. The
stock dilution was titrated on growth medium with
Claster 1
Claster 2
Claster 3
Claster 4
39  % 34 %
2.40 C 2.17 C
22 % 28 %
1.87 C 2.19 C
21  % 20 %
1.75 C 2.11 C
18  % 19 %
2.08 C 2.21 C
A B
Fig. 2. The most probable 3D structures for the V3 loop peptides Gly-
Pro-Gly-Gln-Ala-Phe (A) and Gly-Pro-Gly-Arg-Ala-Phe (B) accor-
ding to MD simulations. The averaged structures are shown for each
structural cluster. The populations of clusters and average distances to
their centers are given below
5-fold step. Concentrations of the test b-GalCer-WSA
ranged from 1.0 mg/ml to 0.0128 µg/ml.
The anti-HIV-1 activity of the glycolipid was deter- 
mined by the MTT-formazan assay [28] in the authors’
version [29]. 
The reaction was carried out using 96-wells tissue
culture panels («Sarstedt», USA) in the volume of the
reaction mixture equal to 200 µl per well. The results
were analyzed in four days by «Plate Reader DAS A3»
(Italy) at 550/630 nm wavelengths.
The trials were put into practice by a therapeutic
scheme, which provides for the introduction of infec-
tious agent to the cell culture after the addition of the test
compound. In each experimental series, azidothymidi-
ne was used as a positive control.
Results and discussion. Analysis of the structural
complexes of glycolipids with theHIV-1 V3 loop pepti-
des. Fig. 3 casts light on the most probable structural
complexes of b-GalCer with the V3 loop peptides ge-
nerated by molecular docking followed by MD simula-
tions. With this analysis, a key role in the formation of
these complexes belongs to the conserved phenylala-
nine of V3 [3, 30] as well as to the galactose residue of
glycolipid. At the same time, H-bonds between sugar
hydroxyl groups and polar atoms of the V3 backbone
greatly contribute to the interactions of V3 with b-Gal
Cer. Among these attractive forces, H-bonds of hydro-
xyl groups in C2, C3 and C4 positions of the pyranose
ring with the carboxyl group of phenylalanine of V3
prevail in the dynamic structures of the complexes of in-
terest. H-bonds between the amino group of the b-Gal
Cer sphingosine base and the carboxyl group of glycine 
3 of the V3 peptides also promote the energy stability
for the supramolecular structures. In addition, H-bond
between the oxygen atom of the fatty acid and the ami-
no group of alanine of V3 is highly probable.
The spatial proximity of the galactose residue to the 
conserved phenylalanine appearing in the structure of
b-GalCer complexed with the V3 peptides (Fig. 3) pro-
vides favorable conditions for making non-conventio-
nal XHLp H-bonds, which may be formed by XH sugar
groups (X designates C or O) and overlapping p-orbi-
tals of the Phe residue due to attractive dispersion for-
ces [31]. These findings fall into line with those of nu-
merous studies (see, e. g., review [32]), whereby CH…
p interactions of the galactose residue with aromatic
amino acids may serve as a determining factor provi-
ding the energy stability of glycosphingolipid/protein
complexes. Exactly this interaction mode, which, accor- 
ding to our simulations, may occur between the conser- 
ved phenylalanine of V3 and b-GalCer, is most likely to 
determine the specificity of the glycolipid binding to
the envelope gp120 protein. This supposition is suppor-
ted by the following rationale: the fatty acid of b-GalCer
is plunged into cellular membrane, and the sugar residue
is the most accessible element of the glycolipid struc-
ture (reviewed in [32]). 
The patterns that b-GalCer displays on binding to
proteins are also observed in the structural complexes
of the free glycolipid with the V3 peptides. In these
complexes, the overwhelming majority of effective
contacts, which include, along with XHLp interac-
tions, intermolecular H-bonds, falls on the carbohydra-
te part of the molecule (Fig. 3). These findings provide
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Phe
Ala
Gln
Gly
Gly
Gly
Gly
Pro
Gal
A B
Sph
Eic
Eic
Sph
Pro
Ala
Arg
Phe
Gal
Fig. 3. Structural complexes of b-GalCer with the V3 peptides Gly-Pro-Gly-Gln-Ala-Phe (A) and Gly-Pro-Gly-Arg-Ala-Phe (B). H-bonds are
shown by dashed lines. The averaged structures for the most probable clusters are indicated. The populations of these clusters for the V3 peptides
Gly-Pro-Gly-Gln-Ala-Phe and Gly-Pro-Gly-Arg-Ala-Phe are 47.6 % and 36.8 % respectively. The following designations are used: Gal  –
galactose; Sph – sphingosine base; Eic – eicosanoic acid
a structural background for designing b-GalCer-WSAs
able to efficiently block the V3 loop by modifications
of the fatty acid residue, which, with the calculated da-
ta, exhibits high conformational mobility and does not
come in the direct contact with V3 (Fig. 3). One of such 
b-GalCer analogs designed with allowing for these in
silico data was tested here for the ability in binding to
V3 by free energy calculations. 
Fig. 4 illustrates the most typical complexes of the
designed analog with the V3 loop peptides in which, as
with b-GalCer, the pyranose ring of galactose and the
conserved Phe of V3 approach each other, and the sugar
hydroxyl groups make H-bonds with polar atoms of the 
V3 backbone. Along with these regularities, the structu-
ral analysis allows one to reveal specific feature cha-
racteristic of the structure of the glycolipid complexed
with the V3 peptide Gly-Pro-Gly-Gln-Ala-Phe (Fig. 4,
A). In this case, the sugar residue is directed at the side-
chain of phenylalanine with its hydrophobic part and
their spatial orientation is preserved for the major por-
tion of the dynamic structures of this supramolecular en-
semble. The high probability of forming such comple-
xes between aromatic compounds and monosacchari-
des is also supported by the NMR spectroscopy data and
quantum chemistry calculations [31, 33, 34]. 
Thus, the findings of molecular modeling clearly
show that, to form the complexes with V3, the designed 
compound may use the structural elements identical to
those, which are utilized by b-GalCer to reach these ob-
jectives. The data obtained, therefore, support the idea
that this compound should keep the capacity for speci-
fic and efficient interactions with V3 characteristic of
the native glycolipid. Examining the free energy of for- 
mation of the complexes of b-GalCer and its analog
with the V3 peptides validates this supposition, which
arise from the analysis of intermolecular interactions
appearing in these supramolecular structures. Indeed,
the design quantities of binding free energy (Table) are
close to the value equal to –10.9 kcal/mol, which was
calculated here from the data on the dissociation con-
stant of the complex of b-GalCer with gp120 [35]. Ne-
vertheless, it should be noted that our calculations con-
cerning the glycolipid structures complexed with Gly-
Pro-Gly-Gln-Ala-Phe result in higher values of binding 
energy in comparison with Gly-Pro-Gly-Arg-Ala-Phe
(Table). It is possible to give the following explanation
for this observation: as opposed to the uncharged gluta- 
mine, the positively charged side-chain of arginine is
more likely to come in the energetically favorable con-
tacts with polar groups of glycolipids, such as hydroxyl 
groups of the galactose residue and the amino group of
the sphingosine base, which should increase the energy 
stability of the corresponding complexes. 
The harmony between the calculated and the em-
pirical data testifies to the correct choice of the compu-
tational procedures, which enabled one to generate the
structural complexes that adequately describe the inter-
actions of glycolipids with V3 despite all approxima-
tions adopted in our simulations. This conclusion is al-
so confirmed by the findings of computer modeling,
which was carried out here to generate the complexes of 
V3 with the modified variant of the designed b-GalCer
analog where the substitution for galactose by glucose
was made. Analysis of these complexes is evidence of
significantly higher free energies of their formation.
This fact goes with the literature data according to which
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A B
Phe
Ala
Gln
Gly
Gly
ProSph
Gal
Phe
Ala
Gly
Gly
Pro
Sph
Arg
Gal
Fig. 4. Structural complexes of the V3 peptides Gly-Pro-Gly-Gln-Ala-Phe (A) и Gly-Pro-Gly-Arg-Ala-Phe (B) with b-GalCer-WSA. H-bonds are 
shown by dashed lines. The following designations are used: Gal – galactose, Sph – sphingosine base
glucosylceramide, unlike b-GalCer, is unable to effecti- 
vely interact with gp120 [7]. 
Test results of b-GalCer-WSA for anti-HIV-1 activi-
ty. As a matter of record, the tested analog of b-GalCer
was shown to display antiviral activity in vitro. Cellular 
protection rating amounts 51–53 % for the glycolipid
concentrations varying from 1.0 to 0.2 µg/ml (as for azi-
dothymidine, this index ranges from 56 to 100 %). At
the same time, maximal tolerant concentration aggrega-
tes 8.0 µg/ml for MT-4 cells, and chemotherapeutic in-
dex of the molecule comes to 40.0, which testifies to its
high anti-HIV-1 activity. 
Thus, the pilot trials of the designed b-GalCer-WSA
validate the conclusion arising from the computer-aided
analysis of the glycolipid structure complexed with the
V3 loop peptides. In this context, the further studies of
this molecule or its structural analogs by confirmatory
tests for HIV-1, such as infectivity assay (e. g., [36]), p24
Elisa (e. g., (www.biochain.com)) and indirect immuno-
fluorescence (e. g., [37]) assays, are highly challenging.
Conclusions. Computer-aided design of b-GalCer-
WSA presenting a potential HIV-1 entry inhibitor was
first carried out here by the analysis of intermolecular
interactions of the intact glycolipid with the V3 loop
peptides, which imitate the core V3 sequence Gly-Pro-
Gly-Arg/Gln-Ala-Phe. The high probability of display- 
ing the antiviral activity was predicted for the simula-
ted molecule by estimating the free energy of formation 
of the structures for this b-GalCer derivative comple-
xed with the V3 loop peptides. These in silico data are
confirmed by the primary anti-HIV-1 assay of the syn-
thesized compound. In the light of these findings, the
designed analog of b-GalCer may be considered as the
basic structure for simulation of its more potent struc-
tural forms, inhibitory properties of which, as follows
from our computations, may be correctly evaluated by
bioinformatics tools. Such an approach to the develop-
ment of novel, V3-based anti-HIV-1 agents, which pro- 
vides for the use of the present-day computer methodo-
logies in the first point of the studies, should give a
chance to make a rational selection of drug candidates
most promising for synthesis and anti-HIV-1 assays. 
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Ком п’ю тер не ко нстру ю ван ня но вих інгібіторів ад сорбції ВІЛ-1,
які бло кують пет лю V3 білка gp120 об олон ки вірусу
Ре зю ме
Мета досліджен ня – на основі аналізу міжмо ле ку ляр них взаємо-
дій гліколіпіду b-га лак то зил це раміду (b-GalCer) з централь ною об- 
лас тю петлі V3 білка gp120 об олон ки вірусу здійсни ти ком п’ю -
тер не ко нстру ю ван ня во до роз чин но го ана ло га b-GalCer – по тен-
ційно го інгібітора ад сорбції ВІЛ-1 – з на ступ ним син те зом цьо го
похідно го гліколіпіду і тес ту ван ням на про тивірус ну ак тивність. 
Ме то ди. Ком п’ю тер не мо де лю ван ня: кван то во-хімічні роз ра -
хун ки, мо ле ку ляр ний докінг, мо ле ку ляр на ди наміка і оцінка вільної
енергії утво рен ня над мо ле ку ляр них струк тур, а та кож ме то ди
хімічно го син те зу та тес ту ван ня на анти-ВІЛ ак тивність. Ре -
зуль та ти.  Для ско нстру йо ва но го ана ло га b-GalCer пе ре дба че но
ви со ку ймовірність про я ву про тивірус ної ак тив ності. Дані мо ле -
ку ляр но го мо де лю ван ня підтвер дже но ре зуль та та ми пер вин них
ме дич них вип ро бу вань син те зо ва ної хімічної спо лу ки. Вис нов ки.
Отри ма ний ана лог b-GalCer мож на роз гля да ти як ба зо ву струк-
туру для мо де лю ван ня його більш ефек тив них модифіко ва них форм 
і подальшо го відбо ру мо ле кул, пер спек тив них для син те зу і тес ту-
вання на анти-ВІЛ ак тивність.
Клю чові сло ва: пет ля V3 білка gp120 ВІЛ-1, гліколіпіди, ком -
п’ю тер не мо де лю ван ня, хімічний син тез, лікарські пре па ра ти
проти СНІДу.
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V3 peptide Glycolipid <DH>, kcal/mol (DH)STD, kcal/mol <TDS>, kcal/mol (TDS)STD, kcal/mol <DG>, kcal/mol (DG)STD, kcal/mol
GPGQAF b-GalCer –27.6 1.1 –18.9 1.2 –8.7 1.6
b-GalCer-WSA –27.5 3.3 –17.8 0.8 –9.7 3.4
GPGRAF  b-GalCer –33.0 2.0 –21.5 0.7 –11.5 2.1
b-GalCer-WSA –29.2 1.9 –19.4 0.7 –9.9 2.0
F o o t n o t e. <DH> and <TDS> designate respectively the mean values of enthalpic and entropic components of free energy; (DH)STD and (TDS)STD
denote the standard deviations corresponding to these values; <DG> and (DG)STD denote respectively the mean values of free energies of
formation of the structural complexes and the corresponding standard deviations.
Free energies of formation of the structural complexes of the V3 loop peptides with b-GalCer and its water soluble analog 
А. М. Андрианов, И. В. Анищенко, М. А. Ки сель, Ю. В. Кор но у шен ко, 
В. А. Ни ко ла е вич, В. Ф. Ере мин, И. И. Ку че ров, А. В. Ту зи ков
Ком пью тер ное ко нстру и ро ва ние но вых ин ги би то ров ад сор бции
ВИЧ-1,  бло ки ру ю щих пет лю V3 бел ка gp120 об олоч ки ви ру са
Ре зю ме
Цель ис следо ва ния –  на осно ве ана ли за меж мо ле ку ляр ных взаимо- 
де йствий гли ко ли пи да b-га лак то зил це ра ми да (b-GalCer) с цент-
ральной об лас тью пет ли V3 бел ка gp120 об олочки ви ру са осу щест-
вить ком пью тер ное ко нстру и ро ва ние во до рас тво ри мо го ана ло -
га b-GalCer – по тен ци аль но го ин ги би то ра ад сор бции ВИЧ-1 – с
по сле ду ю щим син те зом это го про из вод но го гли ко ли пи да и тес-
тиро ва ни ем на про ти во ви рус ную ак тив ность. Ме тоды. Ком пью-
тер ное мо де ли ро ва ние: кван то во-хи ми чес кие рас че ты, мо ле ку -
ляр ный до кинг, мо ле ку ляр ная ди на ми ка и оцен ка сво бод ной энер -
гии об ра зо ва ния над мо ле ку ляр ных струк тур, а так же ме то ды
хи ми чес ко го син те за и тес ти ро ва ния на анти-ВИЧ ак тив ность.
Ре зультаты.  Для ско нстру и ро ван но го ана ло га b-GalCer пред ска-
зана вы со кая ве ро ят ность про яв ле ния про ти во ви рус ной актив но-
сти. Дан ные мо ле ку ляр но го мо де ли ро ва ния под твер жде ны ре-
зульта та ми пер вич ных ме ди цин ских ис пы та ний син те зи ро ванно-
го хи ми чес ко го со е ди не ния. Вы во ды. По лу чен ный ана лог b-GalCer
мож но рас смат ри вать как ба зо вую струк ту ру для мо де ли ро ва -
ния его бо лее эф фек тив ных мо ди фи ци ро ван ных форм и по сле дую-
щего от бо ра мо ле кул, пер спек тив ных для син те за и тес ти ро ва -
ния на анти-ВИЧ  ак тив ность.
Клю че вые сло ва: пет ля V3 бел ка gp120 ВИЧ-1, гли ко ли пи ды,
ком пью тер ное мо де ли ро ва ние, хи ми чес кий син тез, ле ка рствен -
ные пре па ра ты про тив СПИДа.
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